These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1346404)

  • 41. Tamoxifen prophylaxis in breast cancer.
    Love RR
    Oncology (Williston Park); 1992 Jul; 6(7):33-8; discussion 38-40, 43. PubMed ID: 1386239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of tamoxifen as treatment of breast cancer.
    Powles TJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-48-S1-54. PubMed ID: 9045315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tamoxifen and benign breast problems.
    Fentiman IS; Powles TJ
    Lancet; 1987 Nov; 2(8567):1070-2. PubMed ID: 2889976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SERMs for the treatment and prevention of breast cancer.
    Swaby RF; Sharma CG; Jordan VC
    Rev Endocr Metab Disord; 2007 Sep; 8(3):229-39. PubMed ID: 17440819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.
    Iqbal J; Ginsburg OM; Wijeratne TD; Howell A; Evans G; Sestak I; Narod SA
    Cancer Treat Rev; 2012 Jun; 38(4):318-28. PubMed ID: 21775065
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antiestrogen treatment of breast cancer: an overview.
    Pearson OH; Manni A; Arafah BM
    Cancer Res; 1982 Aug; 42(8 Suppl):3424s-3429s. PubMed ID: 7044524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The strategic use of antiestrogens to control the development and growth of breast cancer.
    Jordan VC
    Cancer; 1992 Aug; 70(4 Suppl):977-82. PubMed ID: 1638467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cancer of the breast: primary prevention of breast cancer by tamoxifen, eligibility criteria, alternatives to English proposals].
    Serin D
    Bull Cancer; 1995 Jul; 82 Suppl 3():168s-171s. PubMed ID: 7492829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.
    Curtis MG
    Drug Saf; 2001; 24(14):1039-53. PubMed ID: 11735660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot.
    Jordan VC
    Int J Dev Biol; 2011; 55(7-9):703-12. PubMed ID: 22161827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen and endometrial cancer.
    Segna RA; Dottino PR; Deligdisch L; Cohen CJ
    Mt Sinai J Med; 1992 Oct; 59(5):416-8. PubMed ID: 1435840
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast cancer risk management.
    Reeder JG; Vogel VG
    Clin Breast Cancer; 2007 Dec; 7(11):833-40. PubMed ID: 18269772
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The selective estrogen receptor modulators in breast cancer prevention.
    Li F; Dou J; Wei L; Li S; Liu J
    Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A case of recurrent breast cancer responding to long-term administration of tamoxifen].
    Yayoi E; Kobayashi T; Inaji H; Maeura Y; Mori T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1683-6. PubMed ID: 6433801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial.
    Cuzick J; Forbes JF; Sestak I; Cawthorn S; Hamed H; Holli K; Howell A;
    J Natl Cancer Inst; 2007 Feb; 99(4):272-82. PubMed ID: 17312304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.
    Fink AK; Gurwitz J; Rakowski W; Guadagnoli E; Silliman RA
    J Clin Oncol; 2004 Aug; 22(16):3309-15. PubMed ID: 15310774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.